head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev ET
ISSN: 1312-773X (Online)
Issue: 2017, vol. 23, issue 2
Subject Area: Medicine - Oncology
DOI: 10.5272/jimab.2017232.1532
Published online: 19 April 2017

Review Article

J of IMAB 2017 Apr-Jun;23(2):1532-1535
Deyan DavidovORCID logoCorresponding Autoremail,
Department of Medical Oncology, Medical University, Pleven, Bulgaria.

Objective: The aim of this study was to investigate the prognostic significance for survival of certain clinical and pathological factors in patients with advanced or metastatic colorectal carcinoma (CRC) treated with first- line chemotherapy.
Methods:  From 2002 to 2011 seventy- four consecutive patients with advanced or metastatic CRC, treated in UMHAT- Dr. G. Stranski, Department of Medical Oncology entered the study. Some patient’s characteristics, hematological and pathological parameters, were evaluated for their role as predictors of overall survival. The therapeutic regimens included FOLFOX or FOlFIRI.  Survival analysis was evaluated by Kaplan- Meier test. The influence of pretreatment characteristics as prognostic factor for survival was analyzed using multivariate stepwise Cox regression analyses.
Results: In multivariate analysis a significant correlation was exhibited between survival, poor performance status and multiple sites of metastasis. Variables significantly associated with overall survival in univariate analysis were performance status>1, thrombocytosis, anemia and number of metastatic sites >1.
These results indicated that poor performance status, anemia, thrombocytosis as well as multiple site of metastasis could be useful prognostic factors in patients with metastatic CRC.

Key words: Prognostic factors, Metastatic colorectal carcinoma, Survival,

pdf - Download FULL TEXT /PDF 481 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Davidov D. Prognostic Factors for Survival in Patients with Metastatic Colorectal Cancer Treated with First - Line Chemotherapy. J of IMAB. 2017 Jan-Mar;23(2):1532-1535. DOI: 10.5272/jimab.2017232.1532

Correspondence to: Deyan Davidov, Department of Medical Oncology, Medical University; 1, Kliment Ochridski Boul., 5800 Pleven, Bulgaria; E-mail: dean_davidov@abv.bg

1. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013. CA: A Cancer J Clin. 2013 Jan;63(1):11–30. [CrossRef]
2. Chiang SF, Hung HY, Tang R, Changchien CR, Chen JS, You YT, et al. Can neutrophil-to-lymphocyte ratio predict the survival of colorectal cancer patients who have received curative surgery electively? Int J Colorectal Dis. 2012 Oct;27(10):1347-57. [PubMed] [CrossRef]
3. Li MX, Liu XM, Zhang XF, Zhang JF, Wang WL, Zhu Y, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2014 May 15;134(10):2403-13. [PubMed] [CrossRef]
4. Kohne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002 Feb;13(2):308-17. [PubMed]
5. Díaz R, Aparicio J, Gironés R, Molina J, Palomar L, Segura A, et al. Analysis of prognostic factors and applicability of Koehne’s prognostic groups in patients with metastatic colorectal cancer treated with first- line irinotecan or oxaliplatin- based chemotherapy. Clin Colorectal Cancer. 2005 Sep;5(3):197- 202. [PubMed]
6. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton S, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000 Jul;124(7):979- 994. [PubMed] [CrossRef]
7. Sorbie H, Koehne CH, Sargent DJ, Glimelius B. Patients characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol. 2007 Jul;18(10):1666-1672. [CrossRef]
8. Kaplan EL, Meier P. Non- parametric estimation from incomplete observations. J Am Stat Assoc. 1959; 53(282):457- 481. [CrossRef]
9. Peto R, Pike MC, Armitage P, Breslow N, Cox D, Howard S, et al. Design and analysis of randomized clinical trials requiring prolonged observations in each patient II. Analysis and examples. Br J Cancer. 1977 Jan;35(1)1- 39. [PubMed]
10. Kemeny N, Braun DW Jr. Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. Am J Med. 1983 May;74(5);786-794. [PubMed] [CrossRef]
11. Edler L, Heim ME, Quintero C, Brummer T, Queisser W. Prognostic factors of advanced colorectal cancer patients. Eur J Cancer Clin Oncol. 1986 Oct;22(10):1231-7. [PubMed]
12. Baranyai Z, Krzystanek M, Jуsa V, Dede K, Agoston E, Szasz AM, et al. The comparison of thrombocytosis and platelet-lymphocyte ratio as potential prognostic markers in colorectal cancer. Thromb Haemost. 2014 Mar 3;111(3):483-90. [PubMed] [CrossRef]
13. Assersohn L, Norman A, Cunningam D, Benepal T, Ross PJ, Oates J. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer. 1999 Apr;79(11-12):1800-5. [PubMed] [CrossRef].

Received: 08 January 2017
Published online: 04 May 2017

back to Online Journal